Bank of New York Mellon’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-53,122
| Closed | -$336K | – | 4469 |
|
|
2022
Q4 | $336K | Sell |
53,122
-309
| -0.6% | -$1.71K | ﹤0.01% | 3747 |
|
|
2022
Q3 | $274K | Hold |
53,431
| – | – | ﹤0.01% | 3877 |
|
|
2022
Q2 | $334K | Buy |
53,431
+7,679
| +17% | +$25.9K | ﹤0.01% | 3826 |
|
|
2022
Q1 | $163K | Hold |
45,752
| – | – | ﹤0.01% | 4301 |
|
|
2021
Q4 | $230K | Hold |
45,752
| – | – | ﹤0.01% | 4218 |
|
|
2021
Q3 | $335K | Buy |
45,752
+690
| +2% | +$4.74K | ﹤0.01% | 3995 |
|
|
2021
Q2 | $387K | Buy |
+45,062
| New | +$384K | ﹤0.01% | 3891 |
|
|
2020
Q4 | – | Sell |
-11,285
| Closed | -$60K | – | 4269 |
|
|
2020
Q3 | $60K | Hold |
11,285
| – | – | ﹤0.01% | 4002 |
|
|
2020
Q2 | $66K | Hold |
11,285
| – | – | ﹤0.01% | 3947 |
|
|
2020
Q1 | $42K | Buy |
11,285
+7,511
| +199% | +$38.9K | ﹤0.01% | 3989 |
|
|
2019
Q4 | $24K | Hold |
3,774
| – | – | ﹤0.01% | 4152 |
|
|
2019
Q3 | $52K | Hold |
3,774
| – | – | ﹤0.01% | 4117 |
|
|
2019
Q2 | $56K | Sell |
3,774
-7,515
| -67% | -$201K | ﹤0.01% | 4109 |
|
|
2019
Q1 | $474K | Buy |
11,289
+342
| +3% | +$14.4K | ﹤0.01% | 3581 |
|
|
2018
Q4 | $454K | Buy |
10,947
+607
| +6% | +$27.3K | ﹤0.01% | 3535 |
|
|
2018
Q3 | $498K | Buy |
10,340
+932
| +10% | +$46.7K | ﹤0.01% | 3657 |
|
|
2018
Q2 | $446K | Buy |
+9,408
| New | +$522K | ﹤0.01% | 3677 |
|
Bank of New York Mellon's FSTX Position: Q1 2023 in Review
Bank of New York Mellon sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 53,122 shares — an estimated $336K sold.
Bank of New York Mellon first reported a position in FSTX in Q2 2018 and held it in 17 quarters. The position peaked at $498K in Q3 2018. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.
- Bank of New York Mellon reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Bank of New York Mellon sold 53,122 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $336K.
- Bank of New York Mellon first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2018 and held it in 17 quarters.
- Bank of New York Mellon's F-star Therapeutics, Inc. Common Stock position peaked at $498K in Q3 2018.
- 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.
Based on Bank of New York Mellon's 13F filing for Q1 2023, filed 9 May 2023.